These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6210562)

  • 1. Mezlocillin dose dependent elimination kinetics in renal impairment.
    Aronoff GR; Sloan RS; Stanish RA; Fineberg NS
    Eur J Clin Pharmacol; 1982; 21(6):505-9. PubMed ID: 6210562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonlinear mezlocillin kinetics due to dose-dependent metabolism.
    Gundert-Remy U; Hildebrandt R; Stiehl A; Weber E
    Clin Pharmacol Ther; 1983 May; 33(5):656-62. PubMed ID: 6220858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mezlocillin pharmacokinetics after single intravenous doses to patients with varying degrees of renal function.
    Frimodt-Möller N; Maigaard S; Toothaker RD; Bundtzen RW; Brodey MV; Craig WA; Welling PG; Madsen PO
    Antimicrob Agents Chemother; 1980 Apr; 17(4):599-607. PubMed ID: 6446877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mezlocillin kinetics in hepatic insufficiency.
    Bunke CM; Aronoff GR; Brier ME; Sloan RS; Luft FC
    Clin Pharmacol Ther; 1983 Jan; 33(1):73-6. PubMed ID: 6217018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.
    Mangione A; Boudinot FD; Schultz RM; Jusko WJ
    Antimicrob Agents Chemother; 1982 Mar; 21(3):428-35. PubMed ID: 6213190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mezlocillin disposition in chronic hemodialysis patients.
    Janicke DM; Mangione A; Schultz RW; Jusko WJ
    Antimicrob Agents Chemother; 1981 Nov; 20(5):590-4. PubMed ID: 6459760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function.
    Brogard JM; Comte F; Spach MO; Lavillaureix J
    Chemotherapy; 1982; 28(5):318-26. PubMed ID: 6216076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of intravenous mezlocillin in chronic hemodialysis patients.
    Francke E; Mehta S; Neu HC; Appel GB
    Clin Pharmacol Ther; 1979 Aug; 26(2):228-31. PubMed ID: 455891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
    Rohde B; Werner U; Hickstein H; Ehmcke H; Drewelow B
    Eur J Clin Pharmacol; 1997; 53(2):111-5. PubMed ID: 9403281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mezlocillin in neonatal medicine].
    Sitka U; Weingärtner L; Patsch R
    Infection; 1982; 10 Suppl 3():S158-65. PubMed ID: 6218105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mezlocillin pharmacokinetics in renal impairment.
    Aronoff GR; Sloan RS; Luft FC; Nelson RL; Maxwell DR; Kleit SA
    Clin Pharmacol Ther; 1980 Oct; 28(4):523-8. PubMed ID: 6447570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of piperacillin dose on elimination kinetics in renal impairment.
    Aronoff GR; Sloan RS; Brier ME; Luft FC
    Eur J Clin Pharmacol; 1983; 24(4):543-7. PubMed ID: 6222908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative review of two new wide-spectrum penicillins: mezlocillin and piperacillin.
    Russo J; Russo ME
    Clin Pharm; 1982; 1(3):207-16. PubMed ID: 6224627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of mezlocillin and carbenicillin.
    Pancoast SJ; Neu HC
    Clin Pharmacol Ther; 1978 Jul; 24(1):108-16. PubMed ID: 657712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure.
    Rodondi LC; Flaherty JF; Schoenfeld P; Barriere SL; Gambertoglio JG
    Clin Pharmacol Ther; 1989 May; 45(5):527-34. PubMed ID: 2721108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mezlocillin concentrations in the serum of children with impaired renal function].
    Diekmann L; Niemann A; Ritzerfeld W
    Infection; 1982; 10 Suppl 3():S196-8. PubMed ID: 6218112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics and dosage of mezlocillin administered by intravenous infusion].
    Modr Z; Dvorácek K; Janků I; Krebs V
    Infection; 1982; 10 Suppl 3():S191-5. PubMed ID: 6218111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin.
    Bergan T; Thorsteinsson SB; Steingrimsson O
    Chemotherapy; 1982; 28(3):160-70. PubMed ID: 6212204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.